Psychedelic Biotech Psyence Grows Pipeline With Trials And Psilocybin Drug Developer Acquisition
Portfolio Pulse from Juan Spínelli
Psyence Biomedical Ltd. (NASDAQ:PBM) is advancing its psychedelic-based mental health solutions with a Phase IIb trial in Australia and the acquisition of Clairvoyant. The company is also partnering with Optimi Health (OTC:OPTHF) for psilocybin supply, aiming for significant data readouts in 2025.
September 16, 2024 | 5:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Optimi Health partners with Psyence to supply GMP psilocybin extracts, strengthening its position in the psychedelic supply chain.
Optimi Health's partnership with Psyence for psilocybin supply positions it as a key player in the psychedelic supply chain, potentially increasing its market relevance.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Psyence Biomedical is advancing its psychedelic-based solutions with a new clinical trial and acquisition, potentially leading to significant developments in 2025.
Psyence's initiation of a Phase IIb trial and acquisition of Clairvoyant are significant steps in its development pipeline. These moves could lead to important data readouts in 2025, potentially boosting the company's market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100